Naggie is the first physician in her family, so she describes her path to infectious disease as “an adventure” in which she followed her instincts and her patients’ leads to her final destination. Along her path, Naggie encountered many patients with HIV and subsequently found her niche in infectious disease.
To this day, she values working with patients with HIV and now viral hepatitis through their introduction to and education in the disease space. Naggie wants them to live without either disease defining their parameters. To this end, she considers herself a clinician first and researcher second, with her research driven by her patients — their questions and their need for improved care. Bedside medicine, she said, is something to be treasured.
Currently, Naggie also holds an appointment within the section of GI/Hepatology Research at the Duke Clinical Research Institute where she is principal investigator on several clinical trials of direct-acting antivirals for the treatment of HCV in HIV-infected patients and she staffs two HIV/HCV coinfection multidisciplinary clinics at Duke and the Durham VA Medical Center. She also has active roles with the International Antiviral Society-USA’s Viral Hepatitis Committee and the HCV Guidelines committee through AASLD.
Labels: AASLD, Naggie